STOCKWATCH: How to hide the meaning of clinical data
This article was originally published in Scrip
Investors like to be informed. So it is more than a little frustrating when public companies' clinical trial announcements omit important details; the way the trial was conducted, for instance, or the type of statistical analysis or the nature of the control with which a treatment was compared (scripintelligence.com, 16 July 2013).
You may also be interested in...
The evolution of new drugs to treat diabetes has enabled some diabetes franchises to shrug off biosimilar competition to insulins. But is some of the growth of therapies for diabetes and obesity a result of the pandemic?
Some entrepreneurs combine talent and experience to produce multiple profitable exits for investors. But there are many who do not, and past success is indeed no guarantee of future performance.
In a third-quarter earnings report that was difficult to fault AstraZeneca left big pharma earnings season on a high note. But raised full-year guidance depends on Evusheld sales and maybe China.